Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Haugvik, S-P, Janson, ET, Österlund, P, Langer, SW, Falk, RS, Labori, KJ, Vestermark, LW, Grønbæk, H, Gladhaug, IP & Sorbye, H 2016, 'Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study' Annals of Surgical Oncology, vol. 23, no. 5, pp. 1721-8. https://doi.org/10.1245/s10434-015-5013-2

APA

CBE

MLA

Vancouver

Author

Haugvik, Sven-Petter ; Janson, Eva Tiensuu ; Österlund, Pia ; Langer, Seppo W ; Falk, Ragnhild Sørum ; Labori, Knut Jørgen ; Vestermark, Lene Weber ; Grønbæk, Henning ; Gladhaug, Ivar Prydz ; Sorbye, Halfdan. / Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma : A Nordic Multicenter Comparative Study. In: Annals of Surgical Oncology. 2016 ; Vol. 23, No. 5. pp. 1721-8.

Bibtex

@article{f6f925f0a7dc4b638416551cdfc68505,
title = "Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study",
abstract = "BACKGROUND: This study aimed to evaluate the role of surgery for patients with high-grade pancreatic neuroendocrine carcinoma (hgPNEC) in a large Nordic multicenter cohort study. Prior studies evaluating the role of surgery for patients with hgPNEC are limited, and the benefit of the surgery is uncertain.METHODS: Data from patients with a diagnosis of hgPNEC determined between 1998 and 2012 were retrospectively registered at 10 Nordic university hospitals. Kaplan-Meier curves were used to compare the overall survival of different treatment groups, and Cox-regression analysis was used to evaluate factors potentially influencing survival.RESULTS: The study registered 119 patients. The median survival period from the time of metastasis was 23 months for patients undergoing initial resection of localized nonmetastatic disease and chemotherapy at the time of recurrence (n = 14), 29 months for patients undergoing resection of the primary tumor and resection/radiofrequency ablation of synchronous metastatic liver disease (n = 12), and 13 months for patients with synchronous metastatic disease given systemic chemotherapy alone (n = 78). The 3-year survival rate after surgery of the primary tumor and metastatic disease was 69 {\%}. Resection of the primary tumor was an independent factor for improved survival after occurrence of metastatic disease.CONCLUSIONS: Patients with resected localized nonmetastatic hgPNEC and later metastatic disease seemed to benefit from initial resection of the primary tumor. Patients selected for resection of the primary tumor and synchronous liver metastases had a high 3-year survival rate. Selected patients with both localized hgPNEC and metastatic hgPNEC should be considered for radical surgical treatment.",
keywords = "Adult, Aged, Aged, 80 and over, Carcinoma, Neuroendocrine, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Grading, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Staging, Pancreatic Neoplasms, Prognosis, Retrospective Studies, Scandinavian and Nordic Countries, Survival Rate, Young Adult, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't",
author = "Sven-Petter Haugvik and Janson, {Eva Tiensuu} and Pia {\"O}sterlund and Langer, {Seppo W} and Falk, {Ragnhild S{\o}rum} and Labori, {Knut J{\o}rgen} and Vestermark, {Lene Weber} and Henning Gr{\o}nb{\ae}k and Gladhaug, {Ivar Prydz} and Halfdan Sorbye",
year = "2016",
month = "5",
doi = "10.1245/s10434-015-5013-2",
language = "English",
volume = "23",
pages = "1721--8",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York LLC",
number = "5",

}

RIS

TY - JOUR

T1 - Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma

T2 - A Nordic Multicenter Comparative Study

AU - Haugvik, Sven-Petter

AU - Janson, Eva Tiensuu

AU - Österlund, Pia

AU - Langer, Seppo W

AU - Falk, Ragnhild Sørum

AU - Labori, Knut Jørgen

AU - Vestermark, Lene Weber

AU - Grønbæk, Henning

AU - Gladhaug, Ivar Prydz

AU - Sorbye, Halfdan

PY - 2016/5

Y1 - 2016/5

N2 - BACKGROUND: This study aimed to evaluate the role of surgery for patients with high-grade pancreatic neuroendocrine carcinoma (hgPNEC) in a large Nordic multicenter cohort study. Prior studies evaluating the role of surgery for patients with hgPNEC are limited, and the benefit of the surgery is uncertain.METHODS: Data from patients with a diagnosis of hgPNEC determined between 1998 and 2012 were retrospectively registered at 10 Nordic university hospitals. Kaplan-Meier curves were used to compare the overall survival of different treatment groups, and Cox-regression analysis was used to evaluate factors potentially influencing survival.RESULTS: The study registered 119 patients. The median survival period from the time of metastasis was 23 months for patients undergoing initial resection of localized nonmetastatic disease and chemotherapy at the time of recurrence (n = 14), 29 months for patients undergoing resection of the primary tumor and resection/radiofrequency ablation of synchronous metastatic liver disease (n = 12), and 13 months for patients with synchronous metastatic disease given systemic chemotherapy alone (n = 78). The 3-year survival rate after surgery of the primary tumor and metastatic disease was 69 %. Resection of the primary tumor was an independent factor for improved survival after occurrence of metastatic disease.CONCLUSIONS: Patients with resected localized nonmetastatic hgPNEC and later metastatic disease seemed to benefit from initial resection of the primary tumor. Patients selected for resection of the primary tumor and synchronous liver metastases had a high 3-year survival rate. Selected patients with both localized hgPNEC and metastatic hgPNEC should be considered for radical surgical treatment.

AB - BACKGROUND: This study aimed to evaluate the role of surgery for patients with high-grade pancreatic neuroendocrine carcinoma (hgPNEC) in a large Nordic multicenter cohort study. Prior studies evaluating the role of surgery for patients with hgPNEC are limited, and the benefit of the surgery is uncertain.METHODS: Data from patients with a diagnosis of hgPNEC determined between 1998 and 2012 were retrospectively registered at 10 Nordic university hospitals. Kaplan-Meier curves were used to compare the overall survival of different treatment groups, and Cox-regression analysis was used to evaluate factors potentially influencing survival.RESULTS: The study registered 119 patients. The median survival period from the time of metastasis was 23 months for patients undergoing initial resection of localized nonmetastatic disease and chemotherapy at the time of recurrence (n = 14), 29 months for patients undergoing resection of the primary tumor and resection/radiofrequency ablation of synchronous metastatic liver disease (n = 12), and 13 months for patients with synchronous metastatic disease given systemic chemotherapy alone (n = 78). The 3-year survival rate after surgery of the primary tumor and metastatic disease was 69 %. Resection of the primary tumor was an independent factor for improved survival after occurrence of metastatic disease.CONCLUSIONS: Patients with resected localized nonmetastatic hgPNEC and later metastatic disease seemed to benefit from initial resection of the primary tumor. Patients selected for resection of the primary tumor and synchronous liver metastases had a high 3-year survival rate. Selected patients with both localized hgPNEC and metastatic hgPNEC should be considered for radical surgical treatment.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Neuroendocrine

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasm Grading

KW - Neoplasm Invasiveness

KW - Neoplasm Metastasis

KW - Neoplasm Staging

KW - Pancreatic Neoplasms

KW - Prognosis

KW - Retrospective Studies

KW - Scandinavian and Nordic Countries

KW - Survival Rate

KW - Young Adult

KW - Journal Article

KW - Multicenter Study

KW - Research Support, Non-U.S. Gov't

U2 - 10.1245/s10434-015-5013-2

DO - 10.1245/s10434-015-5013-2

M3 - Journal article

VL - 23

SP - 1721

EP - 1728

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 5

ER -

ID: 49699016